Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand

Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand

Background: Due to limited access to primary percutaneous coronary intervention for the management of ST-segment elevation myocardial infarction (STEMI) in low-to-middle-income countries (LMICs), fibrinolysis serves as a vital alternative reperfusion therapy. Among fibrinolytic agents, the cost-effe...

Full description

Bibliographic Details
Main Authors: Chaiyakunapruk, N. (Author), Dilokthornsakul, P. (Author), Jinatongthai, P. (Author), Le, L.M (Author), Nathisuwan, S. (Author), Paengsai, N. (Author), Sritara, P. (Author), Trerayapiwat, K. (Author), Vathesatogkit, P. (Author)
Format: Article
Language:English
Published: Elsevier Ltd 2022
Subjects:
Cost-effectiveness
Fibrinolytic therapy
Real-world evidence
STEMI
Streptokinase
Tenecteplase
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items